Ignite Creation Date:
2024-05-05 @ 4:46 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00300885
Status:
TERMINATED
Last Update Posted:
2014-11-04
First Post:
2006-03-08
Brief Title:
A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib BAY 43-9006 in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer NSCLC
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib BAY 43-9006 in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer NSCLC
Status:
TERMINATED
Status Verified Date:
2014-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Based on the results of the interim analysis it was determined that the study would not meet its primary efficacy endpoint and the study was terminated early
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A randomized controlled trial comparing safety and efficacy of carboplatin and paclitaxel plus or minus sorafenib in chemonaive patients with stage III-IV non-small cell lung cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2005-005245-19 | EUDRACT_NUMBER | None | None |